Hepatic and Glial Cell Adhesion Molecule (HEPACAM) ELISA Kits

The protein encoded by HEPACAM is a single-pass type I membrane protein that localizes to the cytoplasmic side of the cell membrane. Zusätzlich bieten wir Ihnen Hepatic and Glial Cell Adhesion Molecule Antikörper (57) und Hepatic and Glial Cell Adhesion Molecule Proteine (10) und viele weitere Produktgruppen zu diesem Protein an.

list all ELISA KIts Gen GeneID UniProt
HEPACAM 220296 Q14CZ8
HEPACAM 72927 Q640R3
HEPACAM 521015 A4FUY1
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top Hepatic and Glial Cell Adhesion Molecule ELISA Kits auf antikoerper-online.de

Showing 4 out of 7 products:

Katalog Nr. Reaktivität Sensitivität Bereich Bilder Menge Lieferzeit Preis Details
Human
  96 Tests 26 bis 36 Tage
$899.80
Details
Human
  96 Tests 31 bis 41 Tage
$734.80
Details
Maus < 46.9 pg/mL 78 pg/mL - 5000 pg/mL   96 Tests 11 bis 18 Tage
$838.60
Details
Rind (Kuh)
  96 Tests 15 bis 18 Tage
$1,029.60
Details

Weitere ELISA Kits für Hepatic and Glial Cell Adhesion Molecule Interaktionspartner

Human Hepatic and Glial Cell Adhesion Molecule (HEPACAM) Interaktionspartner

  1. The results suggest that HepaCAM and its cytoplasmic domain suppress the nuclear translocation of AR via Ran in prostate cancer (PCa). The cytoplasmic domain of HepaCAM may serve as a novel target for therapy in PCa.

  2. On the whole, this study indicates that HepaCAM potentially represents a therapeutic target and PF3084014 may prove to a promising agent for use in the treatment of refractory prostate cancer.

  3. hepaCAM associates with connexin 43, a main component of gap junctions, and enhances connexin 43 localization to the plasma membrane at cellular junctions.

  4. this study revealed that hepaCAM was downregulated in CRC tissues and cell lines. Overexpression of hepaCAM inhibited CRC cell proliferation, migration, and invasion in vitro. Furthermore, the tumorigenesis assay showed that increased expression of hepaCAM suppressed CRC tumor growth and metastasis in vivo.

  5. In a group of Egyptian patients with megalencephalic leukoencephalopathy, novel mutations were identified in HEPACAM.

  6. DNMT1 up-regulation induced by IL-6/STAT3 signaling was indispensable for IL-6-mediated hepaCAM loss in renal cell carcinoma (RCC) cell lines ACHN and 769-P, while DNMT3b up-regulation was crucial for hepaCAM loss in A498.

  7. Out of 20 patients, macrocephaly, classic MRI features, motor development delay and cognitive impairment were detected in 20(100%), 20(100%), 17(85%) and 4(20%) patients, respectively. 20(100%) were clinically diagnosed with MLC. 19(95%) were genetically diagnosed with 10 novel mutations in MLC1, MLC1 and GlialCAM mutations were identified in 15 and 4 patients, respectively

  8. HepaCAM depletion was discovered in bladder cancer tissues compared with adjacent normal tissues, and the decreased level was associated with the degradation of FoxO3.

  9. HepaCAM proteins were significantly decreased in bladder carcinoma. Low hepaCAM was not statistically associated with clinicopathological characteristics of the patients. HepaCAM overexpression activated caspase 3/8/9, downregulated poly-ADP ribose polymerase and p-SMAD2/3, and decreased apoptosis.

  10. The suppressive roles of HEPACAM in NSCLC.

  11. Due to the ability to reactivate expression of hepaCAM and inhibit growth of bladder cancer cells, AZAC may represent an effective treatment for bladder cancer.

  12. The extracellular domain of GlialCAM is necessary for cell junction targeting and for mediating interactions with itself or with MLC1 and ClC-2.

  13. HepaCAM may prevent the translocation of PKCepsilon from cytosolic to particulate fractions, resulting in the inhibition of 786-0 cell proliferation.

  14. GlialCAM is able to interact with all CLC channels tested in this study, targeting them to cell junctions and activating them by stabilizing the open configuration of the common gate

  15. Results allow classifying the effect of HEPACAM gene mutations in different subtypes and authors indicate different cellular mechanisms that lead to megalencephalic leukoencephalopathy pathogenesis.

  16. we demonstrate an evolutionary conserved role for MLC1 in regulating glial surface levels of GLIALCAM, and this interrelationship explains why patients with mutations in either gene (MLC1 or GLIALCAM) share the same clinical phenotype.

  17. High expression of hepaCAM is associated with renal carcinoma.

  18. analysis of mutations in GLIALCAM in patients with megalencephalic leukoencephalopathy with subcortical cysts [case report]

  19. results suggested that HepaCAM acted as a tumor suppressor in prostate cancer

  20. Re-activation of hepaCAM gene by 5-aza-CdR can inhibit growth of cancer cells and arrest cells at G0/G1 phase

Mouse (Murine) Hepatic and Glial Cell Adhesion Molecule (HEPACAM) Interaktionspartner

  1. we demonstrate an evolutionary conserved role for MLC1 in regulating glial surface levels of GLIALCAM, and this interrelationship explains why patients with mutations in either gene (MLC1 or GLIALCAM) share the same clinical phenotype.

  2. Data indicate that membrane protein MLC1 is crucial for proper localization of adhesion molecule GlialCAM and chloride channel ClC-2, and for changing ClC-2 currents.

  3. GlialCAM, an immunoglobulin-like cell adhesion molecule is expressed in glial cells of the central nervous system.

Hepatic and Glial Cell Adhesion Molecule (HEPACAM) Antigen-Profil

Beschreibung des Gens

The protein encoded by this gene is a single-pass type I membrane protein that localizes to the cytoplasmic side of the cell membrane. The encoded protein acts as a homodimer and is involved in cell motility and cell-matrix interactions. The expression of this gene is downregulated or undetectable in many cancer cell lines, so this may be a tumor suppressor gene.

Genbezeichner und Symbole assoziert mit HEPACAM

  • hepatic and glial cell adhesion molecule (HEPACAM) Antikörper
  • hepatocyte cell adhesion molecule (Hepacam) Antikörper
  • 2900042E01Rik Antikörper
  • GlialCAM Antikörper
  • Hepn1 Antikörper
  • MLC2A Antikörper
  • MLC2B Antikörper

Bezeichner auf Proteinebene für HEPACAM

hepatocyte cell adhesion molecule , protein hepaCAM

GENE ID SPEZIES
100064233 Equus caballus
220296 Homo sapiens
489305 Canis lupus familiaris
521015 Bos taurus
72927 Mus musculus
Ausgewählte Anbieter für Hepatic and Glial Cell Adhesion Molecule (HEPACAM) ELISA Kits
Haben Sie etwas anderes gesucht?